Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:CAPR NASDAQ:IPSC NASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$28.29-1.7%$29.63$22.24▼$46.00$1.71B0.59759,592 shs561,318 shsCAPRCapricor Therapeutics$26.71-4.4%$31.26$4.30▼$40.37$1.62B0.39997,590 shs574,788 shsIPSCCentury Therapeutics$2.13-3.2%$2.27$0.44▼$3.04$396.78M1.56841,510 shs1.90 million shsSNDXSyndax Pharmaceuticals$17.34-3.8%$21.65$8.59▼$25.59$1.60B0.381.63 million shs2.70 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+4.30%-5.18%+6.01%+5.01%-15.24%CAPRCapricor Therapeutics+1.12%-3.98%-15.20%+0.18%+126.50%IPSCCentury Therapeutics+6.28%-7.56%-3.93%-14.06%+288.01%SNDXSyndax Pharmaceuticals-1.74%-8.76%-10.35%-18.35%+64.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$28.29-1.7%$29.63$22.24▼$46.00$1.71B0.59759,592 shs561,318 shsCAPRCapricor Therapeutics$26.71-4.4%$31.26$4.30▼$40.37$1.62B0.39997,590 shs574,788 shsIPSCCentury Therapeutics$2.13-3.2%$2.27$0.44▼$3.04$396.78M1.56841,510 shs1.90 million shsSNDXSyndax Pharmaceuticals$17.34-3.8%$21.65$8.59▼$25.59$1.60B0.381.63 million shs2.70 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+4.30%-5.18%+6.01%+5.01%-15.24%CAPRCapricor Therapeutics+1.12%-3.98%-15.20%+0.18%+126.50%IPSCCentury Therapeutics+6.28%-7.56%-3.93%-14.06%+288.01%SNDXSyndax Pharmaceuticals-1.74%-8.76%-10.35%-18.35%+64.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$41.4446.50% UpsideCAPRCapricor Therapeutics 2.80Moderate Buy$48.3681.07% UpsideIPSCCentury Therapeutics 2.43Hold$4.75123.00% UpsideSNDXSyndax Pharmaceuticals 2.92Moderate Buy$42.55145.36% UpsideCurrent Analyst Ratings BreakdownLatest IPSC, AGIO, SNDX, and CAPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026SNDXSyndax Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/29/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$41.00 ➝ $40.005/27/2026IPSCCentury Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$8.005/22/2026SNDXSyndax Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/15/2026CAPRCapricor Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.005/13/2026CAPRCapricor Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.005/13/2026SNDXSyndax Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $37.005/1/2026SNDXSyndax Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$35.00 ➝ $37.004/30/2026AGIOAgios Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$39.00 ➝ $36.004/21/2026IPSCCentury Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $5.004/21/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $41.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$54.03M31.14N/AN/A$20.46 per share1.38CAPRCapricor Therapeutics$22.27M69.46N/AN/A$5.53 per share4.83IPSCCentury Therapeutics$109.16M3.52$0.01 per share165.41$1.82 per share1.17SNDXSyndax Pharmaceuticals$172.35M8.91N/AN/A$0.74 per share23.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%7/30/2026 (Estimated)CAPRCapricor Therapeutics-$105.04M-$2.32N/AN/AN/AN/A-59.27%-48.65%8/11/2026 (Estimated)IPSCCentury Therapeutics-$9.58M-$1.14N/AN/AN/AN/A-49.89%-37.42%8/13/2026 (Estimated)SNDXSyndax Pharmaceuticals-$285.42M-$2.79N/AN/AN/A-111.88%-256.65%-45.25%8/3/2026 (Estimated)Latest IPSC, AGIO, SNDX, and CAPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026IPSCCentury Therapeutics-$0.15-$0.11+$0.04-$0.11$2.87 millionN/A5/12/2026Q1 2026CAPRCapricor Therapeutics-$0.55-$0.59-$0.04-$0.59$40.00 millionN/A4/30/2026Q1 2026SNDXSyndax Pharmaceuticals-$0.59-$0.48+$0.11-$0.48$69.76 million$64.86 million4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 million3/12/2026Q4 2025CAPRCapricor Therapeutics-$0.51-$0.62-$0.11-$0.62$0.53 millionN/A3/12/2026Q4 2025IPSCCentury Therapeutics-$0.29-$0.25+$0.04-$0.25($0.08) millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ACAPRCapricor TherapeuticsN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59CAPRCapricor TherapeuticsN/A8.428.42IPSCCentury TherapeuticsN/A10.2510.25SNDXSyndax Pharmaceuticals8.265.475.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ACAPRCapricor Therapeutics21.68%IPSCCentury Therapeutics50.20%SNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%CAPRCapricor Therapeutics9.20%IPSCCentury Therapeutics2.40%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableCAPRCapricor Therapeutics10157.91 million52.58 millionOptionableIPSCCentury Therapeutics170180.35 million176.03 millionOptionableSNDXSyndax Pharmaceuticals11088.61 million84.98 millionOptionableIPSC, AGIO, SNDX, and CAPR HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 4 at 4:01 PM | globenewswire.comSyndax Pharmaceuticals Announces $250 Million Private Placement of Convertible Senior NotesJune 4 at 7:31 AM | quiverquant.comQSyndax Announces Private Placement of $250.0 Million of Convertible Senior NotesJune 4 at 7:00 AM | globenewswire.comSyndax Pharmaceuticals (NASDAQ:SNDX) CFO Keith Goldan Sells 1,177 SharesJune 3 at 6:44 AM | insidertrades.comSyndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant DataJune 2 at 4:01 PM | globenewswire.comSyndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026June 1, 2026 | globenewswire.comAssessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price WeaknessMay 24, 2026 | finance.yahoo.comSyndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant DataMay 21, 2026 | globenewswire.comSyndax Announces Participation in Upcoming Investor ConferencesMay 20, 2026 | globenewswire.comSyndax Pharmaceuticals Inc SNDXMay 19, 2026 | morningstar.comMWhy Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x PotentialMay 14, 2026 | insidermonkey.comSyndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin InhibitionMay 12, 2026 | globenewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 6, 2026 | globenewswire.comSyndax Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 5, 2026 | seekingalpha.comBiotech Momentum Builds As Syndax Pharmaceuticals Draws Market AttentionMay 5, 2026 | kalkinemedia.comKBank of America Securities Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)May 5, 2026 | theglobeandmail.comSyndax Slide Puts Nasdaq Index Biotech in FocusMay 2, 2026 | kalkinemedia.comKSyndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...May 2, 2026 | finance.yahoo.comSyndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting?May 2, 2026 | finance.yahoo.comSyndax: Q1 Earnings SnapshotApril 30, 2026 | stamfordadvocate.comSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPSC, AGIO, SNDX, and CAPR Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$28.29 -0.50 (-1.74%) Closing price 04:00 PM EasternExtended Trading$27.35 -0.94 (-3.34%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Capricor Therapeutics NASDAQ:CAPR$26.71 -1.24 (-4.44%) Closing price 04:00 PM EasternExtended Trading$27.30 +0.59 (+2.19%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Century Therapeutics NASDAQ:IPSC$2.13 -0.07 (-3.18%) Closing price 04:00 PM EasternExtended Trading$2.10 -0.02 (-1.17%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Syndax Pharmaceuticals NASDAQ:SNDX$17.34 -0.68 (-3.77%) As of 04:00 PM EasternSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
